We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
Cap. Flow
-$719M
Cap. Flow %
-15.57%
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$97.5M
2
SGRY icon
Surgery Partners
SGRY
+$75.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$60M
4
PRTA icon
Prothena Corp
PRTA
+$57.7M
5
ARGX icon
argenx
ARGX
+$49.8M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$280M
2
BIIB icon
Biogen
BIIB
+$160M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$120M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$104M
5
HUM icon
Humana
HUM
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
51
Biohaven
BHVN
$2.07B
$20.7M 0.45%
+1,492,000
New +$21.1M
CYTK icon
52
Cytokinetics
CYTK
$10.8B
$19.3M 0.42%
420,700
+85,700
+26% +$3.69M
DCPH
53
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$18.5M 0.4%
1,126,000
-65,800
-6% -$1.07M
CRBU icon
54
Caribou Biosciences
CRBU
$148M
$18.1M 0.39%
2,882,600
-290,000
-9% -$2.58M
ISEE
55
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18M 0.39%
+838,407
New +$17.9M
PNT
56
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$17.7M 0.38%
2,432,400
-387,600
-14% -$2.88M
NSTG
57
DELISTED
NanoString Technologies, Inc.
NSTG
$16.4M 0.36%
2,057,200
+1,359,000
+195% +$11.8M
TWST icon
58
Twist Bioscience
TWST
$5.51B
$14.5M 0.32%
+611,000
New +$17.7M
BCAB icon
59
BioAtla
BCAB
$5.86M
$10.4M 0.23%
+25,200
New +$10.5M
CMPX icon
60
Compass Therapeutics
CMPX
$367M
$10.1M 0.22%
2,000,000
– –
SGMO
61
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.63M 0.19%
2,748,300
+387,500
+16% +$1.5M
ALPN
62
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.56M 0.16%
1,028,200
+29,600
+3% +$189K
KNTE
63
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$7.4M 0.16%
1,212,700
+89
+0% +$725
ANTX icon
64
AN2 Therapeutics
ANTX
$169M
$7.09M 0.15%
743,600
+970
+0.1% +$13K
IPSC icon
65
Century Therapeutics
IPSC
$370M
$6.69M 0.14%
1,303,600
– –
MSAC
66
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.24M 0.11%
520,000
– –
LENZ
67
LENZ Therapeutics
LENZ
$184M
$5.23M 0.11%
225,000
– –
ARYD
68
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$5.05M 0.11%
500,000
– –
PANA
69
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$5.03M 0.11%
500,000
– –
EPIX
70
DELISTED
ESSA Pharma
EPIX
$4.68M 0.1%
1,855,400
-604,600
-25% -$1.74M
OBIO icon
71
Orchestra BioMed
OBIO
$231M
$3.99M 0.09%
400,000
– –
SYRS
72
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.23M 0.07%
900,000
– –
CYT
73
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$2.96M 0.06%
1,795,800
-10,400
-0.6% -$16.7K
CMAX
74
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$2.76M 0.06%
25,178
– –
DNAB
75
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$2.01M 0.04%
200,000
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2022 Portfolio in Review

As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management withdrew a net $719M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials.

Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.

  • Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
  • Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
  • Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
  • Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
  • Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
  • Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.